ClinicalTrials.gg
Not yet recruitingNCT06977438GLOWUpdated Nov 20, 2026

GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward

A Phase 4 interventional study of Semaglutide in Obesity, Childhood, sponsored by University of Minnesota. Not yet recruiting at 1 site in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Minnesota · Phase 4, Interventional, and Treatment

How we know · 4 judgments

Updated Nov 20, 2026Study contact changedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,020
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Pediatric Obesity by University of Minnesota — 1 open to participants now, 1 under way, none of them phase 3. Pediatric Obesity · University of Minnesota.

Planned enrollment
Largest of 19
1,020 · median 80
Started
2027
the only one that year
Phase 4
Only one
of the 20
Registered
20th of 20
by date

Among the 20 studies in Pediatric Obesity by University of Minnesota, this one has the largest planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2027, is the only one in phase 4, and was the 20th registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

1 of the 20 studies in Pediatric Obesity by University of Minnesota is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Pediatric Obesity by University of Minnesota, or all of them as a file.
02

Study summary

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

Read the detailed description

The premise underpinning our proposed project stems from the conceptual framework that obesity medications beneficially alter the underlying pathophysiology that largely drives eating behaviors (appetite, satiety, cravings, and "food noise"), thereby lessening the need for high doses of HBLT. In this way, medications can unburden adolescents living with obesity, their caregivers, healthcare providers, health systems, and payors from the need to engage in and provide intensive HBLT. This framework has directly informed our research strategy and methodological approach, including the design of our trial and the variables we have chosen to assess. Indeed, we plan to compare three different doses of HBLT in terms of their ability to improve health-related outcomes while having a keen eye on nutritional safety and eating disorders. The design and patient-centered outcomes for our trial have been carefully and thoughtfully crafted to provide evidence-based clarity on critical decisional dilemmas regarding how much HBLT is needed to get the most out of obesity pharmacotherapy and how social determinants of health (SDOH) factors can help guide treatment strategies to maximize effectiveness and safety.

03

Conditions studied

  • Obesity, Childhood

Browse trials for

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 12 to \< 18 years at screening
  • >/= 95th percentile based on age and sex at screening
  • Provide release of information for established primary health provider
  • Own a device capable of connecting to the virtual platform sessions with video

Exclusion criteria

Exclusion Criteria:

  • Diabetes (type 1 or 2) due to safety concerns about proper surveillance of glycemic control virtually
  • >/= 6.5%
  • Current or recent (\< 6 months prior to screening) use of FDA-approved obesity medications
  • Previous metabolic/bariatric surgery or metabolic/bariatric surgery planned during the study period
  • Hypertriglyceridemia (TG >/= 500 mg/dL)
  • Any past or current diagnosis of an eating disorder (i.e. anorexia nervosa, atypical anorexia nervosa, bulimia nervosa)
  • Major psychiatric disorder (e.g. schizophrenia, bipolar disorder)
  • Unstable clinically-diagnosed depression, defined as requiring psychiatric hospitalization in the last six months)
  • History of suicide attempt
  • History of suicidal ideation or self-harm within 30 days of screening
  • Patient Health Questionnaire (PHQ-9) score >/= 15 at screening
  • Current pregnancy, breast feeding, or plans to become pregnant
  • Females refusing to use effective
  • Diagnosis of monogenic obesity due to mutations in POMC, PCSK1, or LEPR
  • Diagnosis of syndromic obesity including, but not limited to, Bardet Biedl or Prader-Willi Syndrome
  • History of cholelithiasis without cholecystectomy
  • History of pancreatitis
  • Personal history of first-degree relative history of medullary thyroid carcinoma and/or multiple endocrine neoplasia type 2
  • Known to GLP1 agonists
  • Other participants from the same household who are participating in this trial
  • Any disorder, unwillingness, or inability, which in the investigator's opinion might jeopardize the participant's safety or compliance with the protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,020 participants (estimated)

Study arms

  • Experimental
    High Dose HBLT

    Individuals in this group will be randomized to receive high dose HBLT during the first 52 weeks of the study. The HBLT will consist of group classes with detailed education, skill building and strategies on specific topics in addition to individual goal setting sessions.

    Drug: Semaglutide

  • Experimental
    Medium Dose HBLT

    Individuals in this group will be randomized to receive medium dose HBLT during the first 52 weeks of the study. The HBLT will consist of group classes with condensed information, skill building and strategies in addition to individual goal setting sessions.

    Drug: Semaglutide

  • Experimental
    Low Dose HBLT

    Individuals in this group will be randomized to receive low dose HBLT during the first 52 weeks of the study. The HBLT will consist of group classes with a brief overview of topics in addition to individual goal setting sessions.

    Drug: Semaglutide

Interventions

  • All participants in this study will receive treatment with Semaglutide

06

What researchers measure

Primary outcomes

  1. Body Mass Index (BMI) Reduction

    Change in body mass index

    Time frame: 24 months

07

Study locations

1 site
  • University of Minnesota, Center for Pediatric Obesity Medicine
    Minneapolis, Minnesota 55414, United States
    • Cameron Naughton · Contactnaug0009@umn.edu · 612-625-3623
    • Aaron S Kelly, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Results will be available through the Patient Centered Outcomes Data Repository (PCODR)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be shared after the Patient Centered Outcomes Research Institute (PCORI) accepts the Final Research Report following peer review. As set forth in PCORI's Data Sharing Policy, study data will be available for third-party requests when one of two conditions is met (whichever is met first): PCORI makes the Final Research Report available on the PCORI website At the time of publication of the research project's primary results in a peer-reviewed journal.

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2031, 48 months later.

Of 14 phase 4 interventional studies under Pediatric Obesity, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 70. This study's planned 48 months is close to that.

Start moved 3 times since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, last on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 18, 2025
StartEst.
Jan 1, 2027was Oct 2026
Primary completionEst.
Jan 31, 2031
CompletionEst.
Jan 31, 2032
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 1, 2027
moved 3 times, Oct 2, 2026 – Nov 17, 2026
Contact
Study contact changed: e•••@umn.edu · •••2349→g•••@umn.edu · •••3170. See the current contact
Nov 20, 2026
Show all 4 updates
  1. Nov 20, 2026
    Contact Study contact changed: e•••@umn.edu · •••2349→g•••@umn.edu · •••3170. See the current contact
  2. Nov 17, 2026
    Start date Nov 15, 2026→Jan 1, 2027
    + 1 other change: verification date
  3. Oct 20, 2026
    Start date Oct 15, 2026→Nov 15, 2026
  4. Oct 2, 2026
    Start date Oct 1, 2026→Oct 15, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06977438
Collaborators
Patient-Centered Outcomes Research Institute, Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 18, 2025
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 31, 2031 (estimated)
Completion
Jan 31, 2032 (estimated)
Last update
Nov 20, 2026

Study contacts

Helena Her
Contact
glow@umn.edu
612-624-3170
Aaron Kelly, PhD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion